PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer
Authors
Drewett, L.Lucey, R.
Pinilla, K. A.
Grybowicz, L.
Wulff, J.
Dayimu, A.
Demiris, N.
Vallier, A. L.
Qian, W.
Machin, A.
McAdam, K.
Roylance, R.
Copson, E.
Armstrong, Anne C
Levitt, N.
Provenzano, E.
Tischkowitz, M. D.
McMurtry, E.
Earl, H. M.
Abraham, J.
Affiliation
Department of Oncology, University of Cambridge and Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, CambridgeIssue Date
2022
Metadata
Show full item recordCitation
Drewett L, Lucey R, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, et al. PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305051.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS619Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS619